In the MSK cohort, patients with FGFR2amp were enriched for MYC, RB1, and NMP1 alterations that were not noted on the G360 panel, which could be due to tumor heterogeneity or the low sample size of patients with FGFR2amp in the MSK cohort from a single institution. This evidence concerns the gene RB1 and neoplasm.